We’ve been hearing a lot about vaccines, but this company is thinking of a cure
New Jersey-based pharmaceutical company, Merck, just announced the phase2a findings of their “COVID cure.” The drug, which is an antiviral Therapeutic Molnupiravir, shows promising results amongst patients in early stages of COVID-19. It reduces the presence of the virus and its side effects within an average of 5 days.
See the latest news from Ridgeback Biotherapeutics and Merck on #COVID19 preliminary findings at #CROI2021. Learn more: https://t.co/QZW73RCLOn $MRK pic.twitter.com/DibWgUfJB1
— Merck (@Merck) March 6, 2021
The antiviral, which is a collaboration with Ridgeback Biotherapeutics, is currently in phase 2/3 trials which are due to be completed around May.
Sounds promising…
READ MORE:
Great News: Bahrain Has Officially Hit The 300k Vaccination Benchmark
READ MORE:
Bahrain Is Gearing Up Vaccinations With 300K Additional Doses In March Alone
READ MORE:
Update: You Can Now Choose A Second Preference Vaccine On The BeAware App
